Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance)
- Citation:
- Neurooncol Adv vol 4 (1)
- Year:
- 2022
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- 11
- Parents:
- 2662
- Children:
- None
- Program:
- OGC
- Primary Committee:
- Neuro-Onc
- Sec. Committees:
- Health Outcomes
- Pharmas:
- Grants:
- UG1CA189823, U10CA180821, U10CA180882, UG1CA233180, UG1CA233290, and U10CA180833
- Corr. Author:
- Authors:
- Evanthia Galanis S Keith Anderson Erin Twohy Nicholas A Butowski Adilia Hormigo David Schiff Antonio Omuro Kurt A Jaeckle Shaji Kumar Timothy J Kaufmann Susan Geyer Priya U Kumthekar Jian Campian Caterina Giannini Jan C Buckner Patrick Y Wen
- Networks:
- CA136, LAPS-CT018, LAPS-IL036, LAPS-MA036, LAPS-MN026, NY021, VA009
- Study
- NCCTG-N1174
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 1/2
- Keywords: